Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Prevention and treatment of perioperative bleeding in patients with coagulopathies
Introduction
2013 ESA Guidelines for the Management of Severe Perioperative Bleeding (DO NOT EDIT)[1]
2013 ESA Guidelines for the Management of Severe Perioperative Bleeding (DO NOT EDIT)[1]
Patients with Congenital Bleeding Disorders
von Willebrand Disease
| Class 1 |
| “1. We recommend the use of bleeding assessment tools for predicting the perioperative risk of bleeding. (Level of Evidence: C)” |
| “2. We recommend that patients with vWD be managed perioperatively in collaboration with a hematologist. (Level of Evidence: C)” |
| “3. We recommend desmopressin as a first-line treatment for minor bleeding/surgery in patients with vWD, after a trial testing. The regimen is specified by published guidelines. (Level of Evidence: C)” |
| “4. We recommend replacement of VWF with plasma-derived products for major bleeding/surgery. Treatment regimens are specified by published guidelines. (Level of Evidence: C)” |
| Class 2 |
| “1. We suggest that if vWD is suspected preoperatively, the patient be referred to a hematologist for assessment and planning of the intervention. (Level of Evidence: C)” |
| “2. We suggest that antifibrinolytic drugs be used as hemostatic adjuncts. Treatment regimens are specified by published guidelines. (Level of Evidence: C)” |
| “3. We suggest that platelet transfusion may be used only in case of failure of other treatments. (Level of Evidence: C)” |
Platelet Defects
| Class 1 |
| “1. We recommend the use of a bleeding assessment tool for predicting the perioperative risk of bleeding. (Level of Evidence: C)” |
| “2. We recommend that patients with severe inherited platelet disorders should be managed perioperatively in collaboration with a hematologist. (Level of Evidence: C)” |
| “3. We recommend that rFVIIa treatment should be considered in patients with Glanzmann thrombasthenia undergoing surgery. (Level of Evidence: C)” |
| “4. We recommend against routine platelet transfusion in patients with inherited platelet disorders. (Level of Evidence: C)” |
| Class 2 |
| “1. We suggest referring the patient to a hematologist for assessment and planning of the intervention if inherited platelet defects are suspected preoperatively. (Level of Evidence: C)” |
| “2. We suggest preoperative hemostatic correction in patients with inherited platelet disorders. (Level of Evidence: C)” |
| “3. We suggest desmopressin be used to prevent/control perioperative bleeding in patients with inherited platelet defects. (Level of Evidence: C)” |
| “4. We suggest antifibrinolytic drugs be used as hemostatic adjuncts in procedures involving patients with inherited platelet defects. (Level of Evidence: C)” |
Hemophilia A and B
| Class 1 |
| “1. We recommend that hemophilia patients should be referred preoperatively to a hematologist for assessment/intervention. (Level of Evidence: C)” |
| “2. We recommend that surgery in hemophilia patients should be performed in specialised centres with expertise in coagulation disorders. (Level of Evidence: C)” |
| “3. We recommend adequate perioperative replacement therapy to ensure safe surgery in hemophilia patients. (Level of Evidence: C)” |
| “4. We recommend either recombinant products or plasma-derived concentrates for perioperative replacement therapy in hemophilia patients. (Level of Evidence: C)” |
| Class 2 |
| “1. We suggest that perioperative replacement therapy (target factor level and duration) in hemophilia patients follows published guidelines. (Level of Evidence: C)” |
| “2. We suggest that coagulation factors be given perioperatively by continuous infusion. (Level of Evidence: C)” |
| “3. We suggest either rFVIIa or activated PCCs for hemophilia patients with inhibitors. (Level of Evidence: C)” |
| “4. We suggest antifibrinolytic drugs as perioperative adjunct therapy in hemophilia patients. (Level of Evidence: C)” |
| “5. We suggest individualized perioperative thromboprophylaxis in hemophilia patients. (Level of Evidence: C)” |
Factor VII Deficiency
| Class 2 |
| “1. We suggest that rFVIIa be used in perioperative bleeding due to inherited FVII deficiency. (Level of Evidence: C)” |
| “2. If rFVIIa is given to control perioperative bleeding in inherited FVII deficiency, we suggest lower doses than in hemophilia patients. (Level of Evidence: C)” |
Rare Bleeding Disorders
| Class 1 |
| “1. We recommend that patients with rare bleeding disorders should be referred preoperatively to a hematologist for assessment/intervention. (Level of Evidence: C)” |
| “2. We recommend that surgery in patients with rare bleeding disorders should be carried out in consultation with a hematologist with experience in factor deficiencies. (Level of Evidence: C)” |
References
References
- ↑ 1.0 1.1 Kozek-Langenecker, SA.; Afshari, A.; Albaladejo, P.; Santullano, CA.; De Robertis, E.; Filipescu, DC.; Fries, D.; Görlinger, K.; Haas, T. (2013). “Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology”. Eur J Anaesthesiol. 30 (6): 270–382. doi:10.1097/EJA.0b013e32835f4d5b. PMID 23656742. Unknown parameter
|month=ignored (help)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]